{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:15:17Z","timestamp":1788477317126,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":79,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003968","name":"the Iran National Science Foundation","doi-asserted-by":"crossref","award":["4025310"],"award-info":[{"award-number":["4025310"]}],"id":[{"id":"10.13039\/501100003968","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Academic Centre for Education, Culture, and Research","award":["2907013"],"award-info":[{"award-number":["2907013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-56032-4","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T10:03:23Z","timestamp":1781690603000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A promising combination strategy: oncolytic adenovirus (\u0394E1B-55\u00a0K\/E3) and arsenic trioxide for potent cancer therapy"],"prefix":"10.1038","volume":"16","author":[{"given":"Maryam","family":"Kadkhodazadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Sabri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Pakjoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanam","family":"Sadeghi-Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzaneh","family":"Barkhordari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Bagherian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Sarrami-Forooshani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"issue":"7","key":"56032_CR1","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nbt.2287","volume":"30","author":"SJ Russell","year":"2012","unstructured":"Russell, S. J., Peng, K-W. & Bell, J. C. Oncolytic virotherapy. Nat. Biotechnol. 30 (7), 658\u2013670 (2012).","journal-title":"Nat. Biotechnol."},{"issue":"10","key":"56032_CR2","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/cas.13027","volume":"107","author":"H Fukuhara","year":"2016","unstructured":"Fukuhara, H., Ino, Y. & Todo, T. Oncolytic virus therapy: A new era of cancer treatment at dawn. Cancer Sci. 107(10), 1373\u20131379 (2016).","journal-title":"Cancer Sci."},{"key":"56032_CR3","doi-asserted-by":"publisher","first-page":"1012806","DOI":"10.3389\/fimmu.2022.1012806","volume":"13","author":"M Jafari","year":"2022","unstructured":"Jafari, M. et al. Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses. Front. Immunol. 13, 1012806 (2022).","journal-title":"Front. Immunol."},{"key":"56032_CR4","doi-asserted-by":"crossref","unstructured":"Gujar, S., Pol, J. G. & Kroemer, G. Heating it up: Oncolytic viruses make tumors \u2018hot\u2019and suitable for checkpoint blockade immunotherapies p. e1442169 (Taylor & Francis, 2018).","DOI":"10.1080\/2162402X.2018.1442169"},{"issue":"2","key":"56032_CR5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2174\/1568009618666171129221503","volume":"18","author":"M Liang","year":"2018","unstructured":"Liang, M. Oncorine, the world first oncolytic virus medicine and its update in China. Curr. Cancer Drug Targets. 18(2), 171\u2013176 (2018).","journal-title":"Curr. Cancer Drug Targets"},{"key":"56032_CR6","doi-asserted-by":"crossref","unstructured":"Chahal, J. S., Qi, J. & Flint, S. The human adenovirus type 5 E1B 55\u00a0kDa protein obstructs inhibition of viral replication by type I interferon in normal human cells. (2012).","DOI":"10.1371\/journal.ppat.1002853"},{"issue":"2","key":"56032_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/ncponc0736","volume":"4","author":"T-C Liu","year":"2007","unstructured":"Liu, T-C., Galanis, E. & Kirn, D. Clinical trial results with oncolytic virotherapy: A century of promise, a decade of progress. Nat. Clin. Pract. Oncol. 4(2), 101\u2013117 (2007).","journal-title":"Nat. Clin. Pract. Oncol."},{"issue":"8","key":"56032_CR8","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/sj.cgt.7700727","volume":"11","author":"SR Quist","year":"2004","unstructured":"Quist, S. R., Wang-Gohrke, S., K\u00f6hler, T., Kreienberg, R. & Runnebaum, I. B. Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status. Cancer Gene Ther. 11(8), 547\u2013554 (2004).","journal-title":"Cancer Gene Ther."},{"issue":"10","key":"56032_CR9","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1080\/21645515.2020.1723363","volume":"16","author":"M Mondal","year":"2020","unstructured":"Mondal, M., Guo, J., He, P. & Zhou, D. Recent advances of oncolytic virus in cancer therapy. Hum. vaccines immunotherapeutics. 16 (10), 2389\u20132402 (2020).","journal-title":"Hum. vaccines immunotherapeutics"},{"issue":"6","key":"56032_CR10","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1001\/jamaoncol.2016.2064","volume":"3","author":"SE Lawler","year":"2017","unstructured":"Lawler, S. E., Speranza, M-C., Cho, C-F. & Chiocca, E. A. Oncolytic viruses in cancer treatment: A review. JAMA Oncol. 3(6), 841\u2013849 (2017).","journal-title":"JAMA Oncol."},{"issue":"9","key":"56032_CR11","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrd4663","volume":"14","author":"HL Kaufman","year":"2015","unstructured":"Kaufman, H. L., Kohlhapp, F. J. & Zloza, A. Oncolytic viruses: A new class of immunotherapy drugs. Nat. Rev. Drug Discovery. 14(9), 642\u2013662 (2015).","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"6","key":"56032_CR12","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1002\/cbin.11563","volume":"45","author":"S Yousefnia","year":"2021","unstructured":"Yousefnia, S. Mechanistic effects of arsenic trioxide on acute promyelocytic leukemia and other types of leukemias. Cell. Biol. Int. 45(6), 1148\u20131157 (2021).","journal-title":"Cell. Biol. Int."},{"issue":"6","key":"56032_CR13","first-page":"2102","volume":"94","author":"Y Jing","year":"1999","unstructured":"Jing, Y., Dai, J., Chalmers-Redman, R. M., Tatton, W. G. & Waxman, S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood J. Am. Soc. Hematol. 94(6), 2102\u20132111 (1999).","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"14","key":"56032_CR14","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.3390\/cancers13143386","volume":"13","author":"B Spiesschaert","year":"2021","unstructured":"Spiesschaert, B., Angerer, K., Park, J. & Wollmann, G. Combining oncolytic viruses and small molecule therapeutics: Mutual benefits. Cancers 13(14), 3386 (2021).","journal-title":"Cancers"},{"key":"56032_CR15","doi-asserted-by":"crossref","unstructured":"Simpson, G. R., Relph, K., Harrington, K., Melcher, A. & Pandha, H. Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: Recent advances. Oncol. Virotherapy 1\u201313. (2016).","DOI":"10.2147\/OV.S66083"},{"key":"56032_CR16","doi-asserted-by":"publisher","first-page":"940019","DOI":"10.3389\/fonc.2022.940019","volume":"12","author":"H Scanlan","year":"2022","unstructured":"Scanlan, H., Coffman, Z., Bettencourt, J., Shipley, T. & Bramblett, D. E. Herpes simplex virus 1 as an oncolytic viral therapy for refractory cancers. Front. Oncol. 12, 940019 (2022).","journal-title":"Front. Oncol."},{"issue":"2","key":"56032_CR17","doi-asserted-by":"publisher","first-page":"547","DOI":"10.3390\/v15020547","volume":"15","author":"A Hamad","year":"2023","unstructured":"Hamad, A., Yusubalieva, G. M., Baklaushev, V. P., Chumakov, P. M. & Lipatova, A. V. Recent developments in glioblastoma therapy: Oncolytic viruses and emerging future strategies. Viruses 15(2), 547 (2023).","journal-title":"Viruses"},{"key":"56032_CR18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3389\/fonc.2017.00106","volume":"7","author":"AC Filley","year":"2017","unstructured":"Filley, A. C. & Dey, M. Immune system, friend or foe of oncolytic virotherapy? Front. Oncol. 7, 106 (2017).","journal-title":"Front. Oncol."},{"key":"56032_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coviro.2016.06.009","volume":"21","author":"AR Shaw","year":"2016","unstructured":"Shaw, A. R. & Suzuki, M. Recent advances in oncolytic adenovirus therapies for cancer. Curr. Opin. Virol. 21, 9\u201315 (2016).","journal-title":"Curr. Opin. Virol."},{"issue":"7","key":"56032_CR20","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41568-018-0009-4","volume":"18","author":"K Twumasi-Boateng","year":"2018","unstructured":"Twumasi-Boateng, K., Pettigrew, J. L., Kwok, Y. E., Bell, J. C. & Nelson, B. H. Oncolytic viruses as engineering platforms for combination immunotherapy. Nat. Rev. Cancer. 18(7), 419\u2013432 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"56032_CR21","doi-asserted-by":"crossref","unstructured":"Hays, P. Harnessing the viral replication cycle for oncolytic viral and cancer immunotherapies combination strategies. Viral Replication Cycle-From Pathogenesis and Immune Response to Diagnosis (IntechOpen, 2023).","DOI":"10.5772\/intechopen.1003010"},{"issue":"12","key":"56032_CR22","first-page":"1666","volume":"23","author":"Z-J Xia","year":"2004","unstructured":"Xia, Z-J. et al. Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. Ai zheng= Aizheng= Chin. J. cancer. 23(12), 1666\u20131670 (2004).","journal-title":"Ai zheng= Aizheng= Chin. J. cancer"},{"issue":"1","key":"56032_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41423-022-00956-0","volume":"20","author":"J Chen","year":"2023","unstructured":"Chen, J. et al. Arsenic trioxide elicits prophylactic and therapeutic immune responses against solid tumors by inducing necroptosis and ferroptosis. Cell Mol. Immunol. 20(1), 51\u201364 (2023).","journal-title":"Cell Mol. Immunol."},{"issue":"12","key":"56032_CR24","doi-asserted-by":"publisher","first-page":"9470","DOI":"10.1128\/JVI.72.12.9470-9478.1998","volume":"72","author":"T Rothmann","year":"1998","unstructured":"Rothmann, T., Hengstermann, A., Whitaker, N. J., Scheffner, M. & zur Hausen, H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol. 72(12), 9470\u20139478 (1998).","journal-title":"J. Virol."},{"issue":"3","key":"56032_CR25","first-page":"764","volume":"62","author":"B Geoerger","year":"2002","unstructured":"Geoerger, B. et al. Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res. 62(3), 764\u2013772 (2002).","journal-title":"Cancer Res."},{"issue":"6","key":"56032_CR26","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ccr.2004.11.012","volume":"6","author":"CC O\u2019Shea","year":"2004","unstructured":"O\u2019Shea, C. C. et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell. 6(6), 611\u2013623 (2004).","journal-title":"Cancer cell."},{"issue":"19","key":"56032_CR27","doi-asserted-by":"publisher","first-page":"5713","DOI":"10.7150\/jca.46463","volume":"11","author":"L Wang","year":"2020","unstructured":"Wang, L. et al. A tropism-transformed oncolytic adenovirus with dual capsid modifications for enhanced glioblastoma therapy. J. Cancer. 11(19), 5713 (2020).","journal-title":"J. Cancer"},{"issue":"6","key":"56032_CR28","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1586\/erv.09.29","volume":"8","author":"EE Thacker","year":"2009","unstructured":"Thacker, E. E., Timares, L. & Matthews, Q. L. Strategies to overcome host immunity to adenovirus vectors in vaccine development. Expert Rev. Vaccines. 8(6), 761\u2013777 (2009).","journal-title":"Expert Rev. Vaccines"},{"key":"56032_CR29","doi-asserted-by":"crossref","unstructured":"Wold, W. S. & Tollefson, A. E. (eds) Adenovirus E3 proteins: 14.7 K, RID, and gp19K inhibit immune-induced cell death; adenovirus death protein promotes cell death (Seminars in VIROLOGY, 1998).","DOI":"10.1006\/smvy.1998.0156"},{"issue":"11","key":"56032_CR30","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/nbt887","volume":"21","author":"Y Wang","year":"2003","unstructured":"Wang, Y. et al. E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat. Biotechnol. 21(11), 1328\u20131335 (2003).","journal-title":"Nat. Biotechnol."},{"key":"56032_CR31","doi-asserted-by":"crossref","unstructured":"Si, Y. et al. Targeted E3 region engineering boosts antitumor efficacy of conditionally replicating adenoviruses in an immunocompetent tumor model. Hum. Gene Ther. (2026).","DOI":"10.1177\/10430342251411042"},{"issue":"8","key":"56032_CR32","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nrc3770","volume":"14","author":"BD Lichty","year":"2014","unstructured":"Lichty, B. D., Breitbach, C. J., Stojdl, D. F. & Bell, J. C. Going viral with cancer immunotherapy. Nat. Rev. Cancer. 14(8), 559\u2013567 (2014).","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"56032_CR33","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","volume":"18","author":"K Harrington","year":"2019","unstructured":"Harrington, K., Freeman, D. J., Kelly, B., Harper, J. & Soria, J-C. Optimizing oncolytic virotherapy in cancer treatment. Nat. Rev. Drug Discovery. 18 (9), 689\u2013706 (2019).","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"7","key":"56032_CR34","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/sj.bjc.6604969","volume":"100","author":"I Ulasov","year":"2009","unstructured":"Ulasov, I. et al. Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo. Br. J. Cancer. 100(7), 1154\u20131164 (2009).","journal-title":"Br. J. Cancer"},{"issue":"8","key":"56032_CR35","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.1007\/s12011-022-03500-3","volume":"201","author":"N Yan","year":"2023","unstructured":"Yan, N. et al. Arsenic induces blood\u2013brain barrier disruption and regulates T lymphocyte subpopulation differentiation in the cerebral cortex and Hippocampus associated with the Nrf2 pathway in vivo. Biol. Trace Elem. Res. 201(8), 3981\u20133993 (2023).","journal-title":"Biol. Trace Elem. Res."},{"key":"56032_CR36","doi-asserted-by":"publisher","first-page":"1118246","DOI":"10.3389\/fimmu.2023.1118246","volume":"14","author":"S Asija","year":"2023","unstructured":"Asija, S. et al. Oncolytic immunovirotherapy for high-grade gliomas: A novel and an evolving therapeutic option. Front. Immunol. 14, 1118246 (2023).","journal-title":"Front. Immunol."},{"issue":"3","key":"56032_CR37","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s12272-023-01481-y","volume":"47","author":"M Yan","year":"2024","unstructured":"Yan, M., Wang, H., Wei, R. & Li, W. Arsenic trioxide: Applications, mechanisms of action, toxicity and rescue strategies to date. Arch. Pharm. Res. 47(3), 249\u2013271 (2024).","journal-title":"Arch. Pharm. Res."},{"key":"56032_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s11658-020-00236-7","volume":"25","author":"Y Fang","year":"2020","unstructured":"Fang, Y. & Zhang, Z. Arsenic trioxide as a novel anti-glioma drug: A review. Cell. Mol. Biol. Lett. 25, 1\u201313 (2020).","journal-title":"Cell. Mol. Biol. Lett."},{"issue":"1","key":"56032_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/medsci12010001","volume":"12","author":"S Shah","year":"2023","unstructured":"Shah, S. Novel therapies in glioblastoma treatment: review of glioblastoma; Current treatment options; and novel oncolytic viral therapies. Med. Sci. 12(1), 1 (2023).","journal-title":"Med. Sci."},{"issue":"14","key":"56032_CR40","doi-asserted-by":"publisher","first-page":"3482","DOI":"10.3390\/cancers13143482","volume":"13","author":"M Kamynina","year":"2021","unstructured":"Kamynina, M. et al. Oncolytic virus-induced autophagy in glioblastoma. Cancers 13(14), 3482 (2021).","journal-title":"Cancers"},{"issue":"2","key":"56032_CR41","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.canlet.2009.04.035","volume":"284","author":"Y Li","year":"2009","unstructured":"Li, Y. et al. Arsenic trioxide induces apoptosis and G2\/M phase arrest by inducing Cbl to inhibit PI3K\/Akt signaling and thereby regulate p53 activation. Cancer Lett. 284(2), 208\u2013215 (2009).","journal-title":"Cancer Lett."},{"key":"56032_CR42","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1007\/s13277-015-3040-z","volume":"36","author":"G Jiao","year":"2015","unstructured":"Jiao, G., Ren, T., Guo, W., Ren, C. & Yang, K. Arsenic trioxide inhibits growth of human chondrosarcoma cells through G2\/M arrest and apoptosis as well as autophagy. Tumor Biol. 36, 3969\u20133977 (2015).","journal-title":"Tumor Biology"},{"issue":"19","key":"56032_CR43","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.4161\/cc.5.19.3263","volume":"5","author":"G Cherubini","year":"2006","unstructured":"Cherubini, G. et al. E1B55K-deleted adenovirus (ONYX-015) overrides G1\/S and G2\/M checkpoints and causes mitotic catastrophe and endoreduplication in p53-proficient normal cells. Cell. Cycle. 5(19), 2244\u20132252 (2006).","journal-title":"Cell. cycle"},{"issue":"3","key":"56032_CR44","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3390\/biomedicines10030564","volume":"10","author":"K Gousias","year":"2022","unstructured":"Gousias, K., Theocharous, T. & Simon, M. Mechanisms of cell cycle arrest and apoptosis in glioblastoma. Biomedicines 10(3), 564 (2022).","journal-title":"Biomedicines"},{"key":"56032_CR45","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s12094-019-02054-6","volume":"21","author":"W Huang","year":"2019","unstructured":"Huang, W. & Zeng, Y. A candidate for lung cancer treatment: Arsenic trioxide. Clin. Transl. Oncol. 21, 1115\u20131126 (2019).","journal-title":"Clin. Transl. Oncol."},{"issue":"2","key":"56032_CR46","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2174\/156652312800099599","volume":"12","author":"F Wang","year":"2012","unstructured":"Wang, F. et al. Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice. Curr. Gene Ther. 12(2), 67\u201376 (2012).","journal-title":"Curr. Gene Ther."},{"key":"56032_CR47","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.omto.2018.01.003","volume":"8","author":"AA Al-Zaher","year":"2018","unstructured":"Al-Zaher, A. A. et al. Evidence of anti-tumoral efficacy in an immune competent setting with an iRGD-modified hyaluronidase-armed oncolytic adenovirus. Mol. Therapy-Oncolytics. 8, 62\u201370 (2018).","journal-title":"Mol. Therapy-Oncolytics"},{"key":"56032_CR48","doi-asserted-by":"publisher","first-page":"1039324","DOI":"10.3389\/fmolb.2022.1039324","volume":"9","author":"M Kadkhodazadeh","year":"2022","unstructured":"Kadkhodazadeh, M. et al. Fiber manipulation and post-assembly nanobody conjugation for adenoviral vector retargeting through SpyTag-SpyCatcher protein ligation. Front. Mol. Biosci. 9, 1039324 (2022).","journal-title":"Front. Mol. Biosci."},{"issue":"6","key":"56032_CR49","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3390\/v8060167","volume":"8","author":"SL Wechman","year":"2016","unstructured":"Wechman, S. L. et al. Development of an oncolytic adenovirus with enhanced spread ability through repeated UV irradiation and cancer selection. Viruses 8(6), 167 (2016).","journal-title":"Viruses"},{"issue":"1","key":"56032_CR50","doi-asserted-by":"publisher","first-page":"e0211192","DOI":"10.1371\/journal.pone.0211192","volume":"14","author":"L Crisostomo","year":"2019","unstructured":"Crisostomo, L., Soriano, A. M., Mendez, M., Graves, D. & Pelka, P. Temporal dynamics of adenovirus 5 gene expression in normal human cells. PLoS One. 14(1), e0211192 (2019).","journal-title":"PLoS One"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56032-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56032-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56032-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:23:23Z","timestamp":1788474203000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56032-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["56032"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-56032-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"28 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In this study, all methods were performed in accordance with the relevant guidelines and regulations. Ethical approval was obtained by the Ethics Committee of Motamed Cancer Institute (Ethics code: IR.ACECR.AEC.1402.029).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"27692"}}